Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kevin Schorno"'
Autor:
Kapil N. Bhalla, Adrian Wiestner, Peng Huang, Ari Melnick, John Byrd, Kami Maddocks, Christopher P. Austin, Kevin Schorno, Sumedha Gunewardena, Rekha Rao, Lata Chauhan, Soumyasri Das Gupta, Jinyun Liu, Mondana Ghias, Min Shen, Nakhle Saba, Warren Fiskus
Supplemental Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6d13528985546cfbf8acd33057acf98
https://doi.org/10.1158/0008-5472.22400703.v1
https://doi.org/10.1158/0008-5472.22400703.v1
Autor:
Kapil N. Bhalla, Adrian Wiestner, Peng Huang, Ari Melnick, John Byrd, Kami Maddocks, Christopher P. Austin, Kevin Schorno, Sumedha Gunewardena, Rekha Rao, Lata Chauhan, Soumyasri Das Gupta, Jinyun Liu, Mondana Ghias, Min Shen, Nakhle Saba, Warren Fiskus
Figure Legends for the Supplemental Data.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95ec43fccfc8f73f6e5db6d548ded92b
https://doi.org/10.1158/0008-5472.22400706
https://doi.org/10.1158/0008-5472.22400706
Autor:
Kapil N. Bhalla, Adrian Wiestner, Peng Huang, Ari Melnick, John Byrd, Kami Maddocks, Christopher P. Austin, Kevin Schorno, Sumedha Gunewardena, Rekha Rao, Lata Chauhan, Soumyasri Das Gupta, Jinyun Liu, Mondana Ghias, Min Shen, Nakhle Saba, Warren Fiskus
Chronic lymphocytic leukemia (CLL) exhibits high remission rates after initial chemoimmunotherapy, but with relapses with treatment, refractory disease is the most common outcome, especially in CLL with the deletion of chromosome 11q or 17p. In addre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::971ef7f6371dc091e8bf2272b8cfedc3
https://doi.org/10.1158/0008-5472.c.6505647.v1
https://doi.org/10.1158/0008-5472.c.6505647.v1
Autor:
Kapil N. Bhalla, Adrian Wiestner, Peng Huang, Ari Melnick, John Byrd, Kami Maddocks, Christopher P. Austin, Kevin Schorno, Sumedha Gunewardena, Rekha Rao, Lata Chauhan, Soumyasri Das Gupta, Jinyun Liu, Mondana Ghias, Min Shen, Nakhle Saba, Warren Fiskus
Supplemental Figure 1: Chemical structures of the molecules utilized in this study. Supplemental Table 1: Characteristics of the primary CLL cells utilized in these studies. Supplemental Figure 2: Apoptosis of CLL cells with AF and NAC. Supplemental
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e830ceb95ec1e9aa35177284a8e244c
https://doi.org/10.1158/0008-5472.22400709.v1
https://doi.org/10.1158/0008-5472.22400709.v1
Autor:
Kami J. Maddocks, Mondana H. Ghias, Soumyasri Das Gupta, Kevin Schorno, Sumedha Gunewardena, Ari Melnick, Adrian Wiestner, Peng Huang, Rekha Rao, Lata Chauhan, John C. Byrd, Min Shen, Warren Fiskus, Kapil N. Bhalla, Nakhle S. Saba, Christopher P. Austin, Jinyun Liu
Publikováno v:
Cancer Research. 74:2520-2532
Chronic lymphocytic leukemia (CLL) exhibits high remission rates after initial chemoimmunotherapy, but with relapses with treatment, refractory disease is the most common outcome, especially in CLL with the deletion of chromosome 11q or 17p. In addre
Autor:
Gregory A. Reed, Kevin Schorno, Kathleen E. Heppert, Yulia Jitkova, John L. Haslam, Mark D. Minden, Andre C. Schuh, Donna E. Hogge, Scott Weir, Aaron D. Schimmer, Carolyn A. Goard, Lian G. Rajewski, Karen W.L. Yee, Hong Chang, Joseph M. Brandwein, Marcela Gronda, Vikas Gupta, Debra A. Webster, Rose Hurren, Lavonne Patton, Jim Kasper, Suzanne Trudel
Publikováno v:
American Journal of Hematology. 89:363-368
The antimycotic ciclopirox olamine is an intracellular iron chelator that has anticancer activity in vitro and in vivo. We developed an oral formulation of ciclopirox olamine and conducted the first-in-human phase I study of this drug in patients wit
Autor:
Mark D, Minden, Donna E, Hogge, Scott J, Weir, Jim, Kasper, Debra A, Webster, Lavonne, Patton, Yulia, Jitkova, Rose, Hurren, Marcela, Gronda, Carolyn A, Goard, Lian G, Rajewski, John L, Haslam, Kathleen E, Heppert, Kevin, Schorno, Hong, Chang, Joseph M, Brandwein, Vikas, Gupta, Andre C, Schuh, Suzanne, Trudel, Karen W L, Yee, Gregory A, Reed, Aaron D, Schimmer
Publikováno v:
American journal of hematology. 89(4)
The antimycotic ciclopirox olamine is an intracellular iron chelator that has anticancer activity in vitro and in vivo. We developed an oral formulation of ciclopirox olamine and conducted the first-in-human phase I study of this drug in patients wit
Autor:
Adrian Wiestner, Kevin Schorno, Kapil N. Bhalla, Suman Kambhampati, Mondana H. Ghias, Rekha Rao Manepalli, Scott Weir, Kami J. Maddocks, Christopher M. Austin, Nakhle S. Saba, John C. Byrd
Publikováno v:
Blood. 122:3819-3819
Auranofin (AF) is an oral disease-modifying anti-rheumatic agent. Using a high throughput screening assay of 2,816 FDA-approved drugs against primary tumor cells in vitro, we have previously identified AF as one of five drugs with selective anti-Chro
Autor:
Adrian Wiestner, Mondana H. Ghias, Nakhle S. Saba, Kevin Schorno, Min Shen, Christopher M. Austin, Kapil N. Bhalla, Mohammed Farooqui, Scott Weir
Publikováno v:
Blood. 120:865-865
Abstract 865 Chronic lymphocytic leukemia (CLL), remains incurable, except by allogeneic stem cell transplantation. While multiple chemotherapeutic options are available, relapse and eventually development of chemotherapy resistance are common. Drug
Autor:
Greg Reed, Joseph Brandwein, Hong Chang, Mark D. Minden, Rose Hurren, Lian G. Rajewski, Scott Weir, Lavonne Patton, Suzanne Trudel, Yulia Jitkova, Karen W.L. Yee, Aaron D. Schimmer, Donna E. Hogge, Kevin Schorno, Jim Kasper, Andre C. Schuh, Vikas Gupta, Marcela Gronda
Publikováno v:
Blood. 120:1372-1372
Abstract 1372 Ciclopirox olamine (CPX) is a topical antifungal agent used for the treatment of mild to moderate nail infection. Recently, we and others demonstrated both in vitro and in vivo that CPX chelates intracellular iron and is preferentially